Health Canada approves AMIA Automated Peritoneal Dialysis System

Baxter International recently announced that its AMIA Automated Peritoneal Dialysis (APD) System, which uses the SHARESOURCE Connectivity Platform, has gained approval from Health Canada.

With this approval, Baxter can launch AMIA and SHARESOURCE for Canadian home dialysis patients, who will now have access to treatments that have two-way connectivity to health care teams.

This is the first ADP tool that has gained approval in Canada and the U.S. The technology includes a touchscreen control panel, voice guidance, and two-way telemedicine capabilities, making the treatments more centered around the patients.

“As a leader in home dialysis, Baxter is committed to understanding patients’ and clinicians’ needs, so we can provide innovative therapy options that are designed to support access to care where and when it’s needed,” Stephen Thompson, general manager, region head for Baxter Canada, said. “Baxter’s AMIA with SHARESOURCE system is uniquely designed to help more patients self-administer home PD therapy and allow health care providers the ability to remotely manage their patients’ care.”

AMIA is made with an operator-friendly feature so that more patients can better manage their treatments from their homes. This will benefit countless patients around the world.

The approval specifically helps one out of every 10 Canadians, which is the statistic for patients with chronic kidney disease. People who have end-stage renal disease (ESRD) number 1 in about 24,000 of patients with chronic kidney disease.